Just 12 weeks after launching a StartEngine crowdfunding campaign, Choose Your Horizon has raised over $580,000 from nearly 320 investors.

AUSTIN, Texas, Feb. 7, 2024 — Choose Your Horizon has reached another significant milestone in the company’s first equity fundraising campaign, reaching $580,000 in 12 short weeks. The campaign had a strong start with $100,000 invested in only five days. In the weeks following there has been a steady increase in both the amount invested and the number of investors who are securing shares of the company.

Those who have invested over half a million dollars in Choose Your Horizon come from many different backgrounds. It’s an example of the growing interest in psychedelic therapies. Investors include well-known entrepreneurs Mike Mumola, Luis Berruga – former CEO of Global X, a leading ETF firm. Medical professions and patients are also among the investors as well as individuals who work with and for Choose Your Horizon.

Choose Your Horizon’s proprietary telehealth wellness platform connects patients in need with medical specialists who can prescribe at-home ketamine treatments for depression, anxiety and PTSD. Part of the therapy includes integration work and sessions with guides that help before and during the treatment. Already the company’s telehealth platform has helped facilitate thousands of successful, safe treatments for 1,800+ patients, of which 98% have reported an improvement in their symptoms.

Choose Your Horizon is continuing to meet and exceed its operating goals as the company works toward nationwide coverage for their wellness platform. With the equity from the StartEngine crowdfunding campaign Choose Your Horizon is poised to expand into all 50 states by the end of 2024. The company has also grown its Medical Advisory Team and recently established an Integration Team.

For the remainder of the equity fundraising campaign Choose Your Horizon is offering all investors volume-based incentives as well as incentives for repeat investors.

“The strong support we’ve had from top-level executives to patients to our own team members is incredible and shows how many believe in our company,” said Founder and CEO, Mark Holland. “Getting support from professionals in the medical field has also been very rewarding since they play a pivotal role in making new therapies widely available.”

Investors who would like to know more about the evolving psychedelic therapy industry, see performance metrics for Choose Your Horizon or read clinical evidence that supports the use of psychedelics for certain mental health conditions can visit the Choose Your Horizon StartEngine campaign page to learn more.

ABOUT CHOOSE YOUR HORIZON, INC.
Choose Your Horizon operates a proprietary telehealth platform that is purpose-built to connect clinicians with patients who are in need of psychedelic therapies for anxiety, depression and PTSD. Leveraging telemedicine technologies, certified medical experts can use the Choose Your Health platform to facilitate safe at-home treatments. Choose Your Horizon is dedicated to developing highly therapeutic customer journeys that are effective, affordable and accessible to all. 

Media Contact:
Rob Lee
202-963-1356
[email protected] 

SOURCE Choose Your Horizon

NEW YORK, Feb. 7, 2024 — Coalesce Capital (“Coalesce”), a private equity firm investing in human capital-driven and technology-enabled services companies, today announced the closing of its inaugural fund, Coalesce Capital Fund I LP (the “Fund”), and parallel vehicles, with $900 million in total capital commitments. The Fund was oversubscribed and secured investor commitments in nine months, above its original target of $750 million. Coalesce now has approximately $1.0 billion in regulatory assets under management.

The Fund’s globally diversified investor base is comprised of leading endowments, foundations, healthcare and pension systems, financial institutions and entrepreneurs. Coalesce has begun deploying the Fund and recently completed its first investment in Examinetics, a leading provider of occupational health compliance testing services.

“Coalesce was formed to partner with ambitious entrepreneurs leading human capital- and technology-enabled services businesses. Our goal is to accelerate the growth of these companies by applying our financial capital and collaborative value creation approach,” said Stephanie Geveda, Founder and Managing Partner of Coalesce. “We are grateful for the support of our Fund I investors on this journey and are working hard to reward their trust as we identify and invest behind the category-leading platforms of tomorrow.”

PJT Park Hill served as the exclusive placement agent, subject to certain exclusions; Latham & Watkins LLP served as fund formation counsel.

About Coalesce Capital

Coalesce Capital is a private equity firm that partners with entrepreneurs and management teams to build enduring value around differentiated businesses. Dedicated to investing in human capital-driven and technology-enabled services companies, the firm’s growth-oriented investment philosophy centers around its conviction that people are the most important ingredient of value creation. Coalesce leverages its sector expertise, strategic resources and capital to collaborate with management teams to create shared success. For more information, visit: www.coalescecap.com. Follow Coalesce on LinkedIn: @Coalesce. 

Media Contact

Ed Trissel / Sarah Salky
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
[email protected] 

SOURCE Coalesce Capital

Scion debuts as a biotech company formation specialist, dedicated to creating clinically important medicines and with the right structure and resources to support its most promising portfolio companies through to maturity as late- or commercial-stage biopharmaceutical enterprises

NEW YORK, Feb. 7, 2024 — Scion Life Sciences (“Scion”), an affiliate of Petrichor, is a New York City-based life sciences venture capital firm dedicated to founding and building exceptional biotechnology companies that discover, develop, and seek to commercialize clinically transformational or curative new medicines, today announced the final close of its inaugural fund, which was oversubscribed with $310 million in capital commitments.

Scion was founded and is led by longstanding partners and experienced company-builders and investors Samuel W. Hall, PhD, and Aaron M. Kantoff, together with Tadd S. Wessel, founder, and Managing Partner of Petrichor. Scion’s mission is to create medicines that cure or transform the clinical management of serious and life-threatening diseases and this overriding objective informs every aspect of the firm’s strategy and approach. Scion forms and builds companies around translational innovations with the right bone structure to become clinically important medicines and is structured to support portfolio companies with the long-term capital and operational resources required to realize the mature clinical potential of the therapies they discover and develop. Scion is able to make initial investments as small as a few thousand dollars in early-stage incubation efforts but is resourced to cumulatively deploy $60 million or more over the life of each portfolio company investment and to support promising portfolio companies from pre-seed stage through to IPO and beyond.

Scion’s strategic and pragmatic approach to investment and innovation is honed by experience, supported by historical industry data, and actualized through disciplined and scaled capital deployment. The firm leverages an asset selection strategy built on three investment pillars to mitigate risk and increase the probability of delivering transformational medicines for patients:

• Invest in therapeutic modalities and enabling technologies that are sufficiently mature to make clinically important medicines today or in the near term
• Invest in therapeutic areas, diseases, and drug targets where deep understanding of the underlying science makes powerful intervention possible
• Focus on clinical problems that can be addressed with the resources available to an independent biotechnology company

“We believe that solving clinically important problems is the fundamental driver of value creation in the life sciences industry and that sustained, long-term support is critical to building companies capable of generating these solutions,” said Sam Hall, PhD, co-founder, and Managing Partner of Scion Life Sciences. “These convictions determine where we invest our capital and human resources and how we build our portfolio companies.”

Scion has established an experienced team of scientific, medical, financial, technological, and operational leaders that enable an active approach to founding and building companies and to create or refine innovative therapeutic substrate internally. The Scion team has begun investing its inaugural fund with four promising company formation efforts underway. Details of the fund’s growing portfolio will be disclosed subsequently as ongoing company builds mature and additional efforts are initiated.   

To further enhance capabilities, the team also established Scion Innovations to provide in-house R&D capabilities and operational resources. This equips Scion with the information and technology to make efficient, objective decisions and helps to ensure that only programs with exceptional potential mature into full-scale portfolio company investments.

“We build companies with the primary objective of creating important new medicines, not exits,” added Aaron Kantoff, co-founder, and Managing Partner of Scion Life Sciences. “Our proactive and data-driven approach to company building allows us to generate a concentrated portfolio of best ideas, optimized to yield real medicines that change the lives of patients and caregivers. This objective, along with our long duration fund structure, enable us to build sustainably operating biotechnology companies, that are capable of ascending to valuations in the tens of billions as they commercialize clinically transformational new medicines.”

“We appreciate the trust of our limited partners that share the Scion team’s conviction in the profound economic and societal value creation potential of clinically important new medicines,” said Tadd Wessel, co-founder, and Managing Partner of Scion Life Sciences and Petrichor. “Sam and Aaron have established themselves as exceptional investors and company builders and the outlier success of the companies they have previously built together provides impressive validation of their unique approach. I and the entire Petrichor team are delighted to partner with them in building Scion.”

About Scion Life Sciences
Scion Life Sciences, an affiliate of Petrichor, is a life sciences venture capital firm committed to meaningfully improving human health through long-term ownership of clinically transformative therapies. Our team of experienced innovators, company-builders and investors is founding and building exceptional biotechnology companies to discover, develop, and commercialize clinically transformational or curative new medicines. We aim to support impactful and sustainable advancements with a strategic and pragmatic approach to investment and innovation. For more information, please visit www.scionlifesciences.com.

About Petrichor
Petrichor partners with world-class healthcare managers and businesses to provide customized investment structures and support. The Petrichor team has completed over 125 investments representing more than $6 billion in invested capital and has held over 55 board seats. Petrichor maintains a deep in-house understanding of healthcare products and services, including scientific, technical, and commercial expertise. This healthcare expertise, together with a breadth of experience investing across sectors, geographies, and capital structures, provides a unique combination to help build successful companies.  For more information, please visit www.petrichorcap.com.

About the Scion Life Sciences Leadership

Samuel W. Hall, PhD
Sam is a founder and Managing Partner of Scion. He has more than 20 years of experience in the life sciences across roles as an investor, scientist, and entrepreneur. From 2013 until October 2019, Sam was a Partner at Apple Tree Partners (ATP), where he focused on creating and building therapeutics companies. During his tenure at ATP, Sam contributed to the formation, financing and build-out of Syntimmune (acquired by Alexion Pharmaceuticals), Stoke Therapeutics, Chinook Therapeutics (acquired by Novartis), Marengo Therapeutics and Ascidian Therapeutics and served as a member of each company’s Board of Directors.

Prior to joining ATP, Sam was an immunologist at the University of Cambridge. Prior to returning to academia, Sam was a member of the investment team at Symphony Capital and began his career as an investment banker at Citigroup.

Aaron M. Kantoff
Aaron is a founder and Managing Partner of Scion. He has spent over a decade specializing in founding, building, and investing in life sciences companies, focusing primarily on therapeutics. Aaron currently serves as a board member of Tourmaline Bio, where he has been serving since the company’s inception. Previously, he was a Venture Partner at Medicxi, where he was a founding board member of Centessa Pharmaceuticals PLC and assisted the team with other privately-held therapeutics investments. Before joining Medicxi, he was a co-founder and board member of RayzeBio, which was recently acquired by Bristol Myers Squibb.

From 2011 until 2019, Aaron was a Partner at Apple Tree Partners (ATP), a New York-based life sciences venture capital firm. At ATP, Aaron was a key member of the therapeutics investment practice, playing a leading role in assembling several ATP portfolio companies, and most notably, serving on the boards of Akero Therapeutics, Corvidia Therapeutics (acquired by Novo Nordisk) and Syntimmune (acquired by Alexion), as well as two privately-held companies (Marengo and Ascidian). During his time at ATP, Aaron was also a board observer at Stoke Therapeutics.

Tadd S. Wessel
Tadd is the founder and Managing Partner of Petrichor, a private investment firm focused on the healthcare sector.  He is also a founder and Managing Partner of Scion.  Tadd has more than 25 years of healthcare finance experience, primarily focused on the life sciences sectors. Previously, he was a Partner at OrbiMed Advisors, where he led the build-out of the structured investment business. Prior to OrbiMed, Tadd was a Vice President at Fortress Investment Group focused on healthcare investments.

Tadd has served on more than 30 boards most recently including Aurion Biotech, Cryoport, and ITM. He also serves on the Advisory Board of the AIM at Melanoma Foundation, whose mission is dedicated to finding more effective treatments and, ultimately, the cure for melanoma.  He also serves on the Board of the International Centers for Precision Oncology (ICPO) whose mission is to scale access of molecularly targeted precision oncology diagnostics and therapeutics for the benefit of cancer patients globally.

SOURCE Scion Life Sciences

Start-up Welcomes Cybersecurity Veterans to Board of Directors

LONDON, Feb. 7, 2024 — Device Authority, a global leader in Identity and Access Management for Enterprise IoT ecosystems, announced $7M in Series A funding from Ten Eleven Ventures, a global venture capital firm specializing in cybersecurity. The investment follows Device Authority’s prestigious Microsoft Global Partner of the Year award and the launch of the company’s new KeyScaler AI solution.

The growing complexity of Enterprise IoT ecosystems makes device security increasingly vital. As the global number of IoT devices is projected to reach 41.6 billion by 2025 and the number of IoT-focused cyber attacks rose to over 112 million in 2022 according to Statista, effective identity and access management is a foundational element in mitigating security risks, preventing unauthorized access, and ensuring compliance.

Device Authority’s KeyScaler-as-a-Service (KSaaS) platform provides automated device identity security throughout the entire lifecycle, allowing organizations to achieve end-to-end device and data trust. Its patented Dynamic Device Key Generation (DDKG) trust anchor technology and its continuous authorization supports supply chain security and establishes a vital root of trust to mitigate the security risks posed by the use of AI in connected environments in the automotive, medical, industrial, and critical infrastructure industries.

The Series A investment enables Device Authority to continue to grow its product offerings and will allow the company to continue to expand its North American presence. Alongside the investment, Device Authority appointed three new board members, including industry luminary and serial cyber CEO and investor Timothy Eades who joins as Chair of the Board; Dave Palmer, General Partner of Ten Eleven Ventures and co-founder and Chief Product Officer of Darktrace; and Grace Cassy, co-founder of cybersecurity investment firm CyLon Ventures and former foreign policy advisor to UK Prime Minister Tony Blair.

Device Authority’s CEO Darron Antill commented, “We are delighted to welcome Ten Eleven Ventures as a new investor. This investment is a significant step in Device Authority’s journey as we continue to help new and existing customers solve their device security challenges. The wealth of knowledge and experience that our new investor and board members bring will add significant value in helping the company grow and become the market leader for delivering zero trust for IoT.”

Ten Eleven Ventures General Partner Dave Palmer added, “The Device Authority team is solving a critical and huge problem in cybersecurity: how to enable complete IoT devices and data trust. Through the company’s KeyScaler platform, the company has developed a comprehensive way in which companies can manage the risks of smart components and ultimately deliver safer products to their consumers. We are pleased to partner with them at this chapter of their journey, and look forward to helping them grow.”

About Device Authority:
Device Authority secures the connected future by automating Zero Trust security at scale and is a recognized global leader in Identity and Access Management (IAM) for Enterprise IoT ecosystems. Device Authority’s KeyScaler identity security platform and KeyScaler-as-a-Service (KSaaS) allow organizations to reduce human error and accelerate incident response, minimizing risk, ensuring complete device and data trust, and enabling trusted AI in any connected environment. Keep updated by visiting www.deviceauthority.com, following @DeviceAuthority and subscribing to our BrightTALK channel.

About Ten Eleven Ventures:
Ten Eleven Ventures is the original cybersecurity-focused, global-stage agnostic investment firm. The firm finds, invests, and helps grow top cybersecurity companies addressing critical digital security needs, tapping its team, network, and experience to help build successful businesses. Since its founding, Ten Eleven Ventures has raised over $US 1 billion and made over 50 cybersecurity investments across stages worldwide, including KnowBe4, Darktrace, Axis Security, Twistlock, Verodin, Cylance, and Ping Identity. For more information, please visit 1011vc.com. 

Media Contact:
Danielle Ostrovsky
Hi-Touch PR
[email protected]

SOURCE Device Authority

Stephan Roche joins as CEO to lead the VC firm into the next stage of growth and expand its network of investors and entrepreneurs.

SAN FRANCISCO, Feb. 6, 2024 — SemperVirens, a leading Venture Capital firm investing in technology companies reshaping the world of health, wealth, and work, today announced the appointment of Stephan Roche as CEO.

Roche joins SemperVirens with a track record of leading and scaling high-performance teams that achieve impressive results, including serving as a top executive at two of the largest family offices in the world. In his most recent role, Roche served as CEO of a multigenerational family office, leading them through a period of significant growth and transformation. During his tenure, he led the creation of an institutional-class in-house investment team that oversees an extensive portfolio across diverse asset classes, including direct investments. Earlier in his career, Roche was an entrepreneur in fintech, one of SemperVirens’ core areas of investment focus.

As CEO of SemperVirens, Roche will partner with the investment team to accelerate the growth of the firm. He will support its strategy of securing early stakes in the new winners of the world of work and bring an operator’s mindset to help amplify their growth. Core to this is the SemperSystem™, a proprietary operating system built on SemperVirens’ network of investors, entrepreneurs, expert advisors, employers, and strategic distribution partners. The SemperSystem serves as a unique growth engine for our portfolio companies by providing exclusive go-to-market deals, expert operating support, and deep market insights tailored to each company’s specific needs.

“Stephan’s combination of experiences as an entrepreneur and proven strategic leader make him an ideal person to serve as CEO of SemperVirens,” said Greg Golub, co-founder of SemperVirens. “He brings a wealth of capabilities to build on our momentum as the leading investor in next generation companies that are creating a more inclusive, human-centered global economy.”  

“With his dedication to operational rigor and growth, we are confident that Stephan’s skills will complement our investment team and help shape our existing foundation,” said Robby Peters, co-founder and General Partner of SemperVirens. “This addition is perfect for delivering our unique venture investing model, including our proven approach to supporting innovative companies.”

About SemperVirens:

SemperVirens is a leading venture capital firm investing in B2B tech startups reshaping the worlds of health, wealth and work. The SemperSystem™ – a proprietary operating system built on SemperVirens’ network of investors, entrepreneurs, expert advisors, employers, and strategic distribution partners – amplifies the performance of the firm’s portfolio companies and funds. SemperVirens has $225 million AUM, and a portfolio of 60 companies. For more information, visit www.sempervirensvc.com.

SOURCE SemperVirens Venture Capital

BOSTON, Feb. 6, 2024 — LearnLaunch Fund + Accelerator, the trailblazing supporter of innovation in the education and workforce sectors since its first program in 2013, announces that applications are open for its next “Breakthrough to Scale” program. Since its inception, LearnLaunch has successfully invested in 81 companies through 13 accelerator cohorts. It is committed to addressing the challenges faced by emerging, early-revenue stage education technology and workforce upskilling companies.

Breakthrough to Scale is a strategic accelerator program tailored to help early-revenue stage edtech and workforce upskilling companies navigate the complexities of scaling in the education market. The program provides participating companies with capital, expert guidance from experienced Venture Partners and mentors, and follow-on investment upon completion of milestones defined in the program. The program focuses on helping early-revenue stage companies find strong product-market fit, build repeatable and scalable sales, develop measurable impact metrics, and identify viable funding pathways.

LearnLaunch’s impact track record underscores its dedication to advancing the education landscape across K-12, higher ed, and workforce upskilling. The companies backed by LearnLaunch have collectively impacted over 40 million learners and raised more than $270 million in additional capital.

A key catalyst for LearnLaunch’s impact is a continued strategic partnership and fund investment from ECMC Foundation. ECMC Foundation is dedicated to improving higher education for career success among underserved populations through evidence-based innovation. This approach closely aligns with LearnLaunch’s mission. ECMC Foundation’s support will allow LearnLaunch to expand its reach and create equitable post-secondary educational opportunities.

ECMC Foundation’s President Jacob Fraire said “This edtech fund is highly catalytic for the sector to help close financial and equity gaps and build sustainable solutions,” said Jacob Fraire, president of ECMC Foundation. “With this investment in LearnLaunch’s third fund, we can multiply these efforts and are especially pleased to see LearnLaunch’s track record of two-thirds of its founders being women and/or entrepreneurs of color. Our organizations share an understanding that impact and innovation are optimized from supporting underrepresented groups.“

Applications for the new Breakthrough to Scale program open on Feb 5th. While the program is open to all companies in K-12, higher education, and workforce upskilling, this cohort will be particularly focused on companies targeting skills development and competency-based learning, employability tools, and AI-enabled edtech solutions. LearnLaunch encourages interested entrepreneurs and other potential supporters to reach out to [email protected].

SOURCE LearnLaunch Fund + Accelerator

CHICAGO and MEXICO CITY, Feb. 6, 2024 — Creation Investments Capital Management, LLC, a leading global impact investor in emerging markets, today announced its participation in a $3.4 million bridge funding round to further support the expansion of Techreo, a Mexico City-based digital financial services platform. G2 Momentum, a venture capital firm in Mexico City, was also part of the financing round.

“We are confident in our mission to provide comprehensive financial services to an underserved population in Latin America,” said Iliana de Silva, CEO and co-founder of Techreo. “We are committed to being a catalyst for change in this region, leveraging our expansion into Bolivia to focus on Peru, Colombia, Ecuador, and the Hispanic population in the United States.”

The Techreo platform is a leader in the Latin America financial technology ecosystem, demonstrating sustainable growth in its two years of existence and offering comprehensive financial services digitally to more than 440,000 users in Mexico and more than 40,000 in Bolivia.

From offices in Chicago, Mexico City, and Bangalore, Creation Investments currently manages $2.1 billion in assets. Since inception in 2007, Creation has invested in 31 portfolio companies operating across eight countries and is focused on financial services and financial inclusion for the unbanked and underbanked population in emerging markets.

“We are pleased to invest in this new financing round to support Techreo’s growth initiatives,” said Amadeo Ibarra, Mexico country head of Creation Investments. “Techreo has an impressive track record of profitably executing its strategic vision to promote financial inclusion in Mexico with a digital app uniquely designed to serve people at the base of the economic pyramid.”  

About Techreo
Techreo is a leading platform for comprehensive financial services in Mexico, committed to driving financial inclusion in Latin America. Since its launch in 2022, it has captured the attention of more than 440,000 users in Mexico and more than 40,000 in Bolivia, along with a capital raise of $6 million. With a presence in strategic markets of Latin America, such as Bolivia, Techreo combines innovation, simplicity, and cutting-edge technology to democratize access to financial tools, education, and business solutions, thus transforming the relationship of individuals and businesses with the financial world. To learn more about Techreo, visit https://techreo.mx/, Facebook and LinkedIn.

About Creation Investments
Creation Investments Capital Management, LLC is a leading global impact investment manager in emerging markets. Creation Investments seeks out the next generation of financial services firms focused on increasing access to capital and providing financial products to the unbanked and underbanked in emerging markets. The firm aims to improve the lives of those living at the bottom of the economic pyramid, reducing poverty and its ill effects in the developing world through market-based solutions. Creation Investments is headquartered in Chicago and has offices in Bangalore, Dallas, and Mexico City. As of Sept. 30, 2023, Creation Investments had $2.1 billion in assets under management. To learn more, visit www.creationinvestments.com.

Media Contacts:

Margaret Kirch Cohen
Newton Park PR, LLC
M: +1 847-507-2229
[email protected]

Rich Chimberg
Newton Park PR, LLC
M: +1 617-312-4281
[email protected]

SOURCE Creation Investments Capital Management, LLC

CARMEL, Ind., Feb. 6, 2024 — Syra Health Corp. (NASDAQ: SYRA) (“Syra Health” or the “Company”), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today it has been awarded a one-year contract with the District of Columbia’s Department of Behavioral Health worth approximately $250,000.

The D.C. Department of Behavioral Health provides prevention, intervention, and treatment services and support for children, youth, and adults with mental and/or substance use disorders including emergency psychiatric care and community-based outpatient and residential services.

Under the contract, Syra Health will conduct an epidemiological study aimed at identifying the prevalence and types of behavioral health conditions that exist among youth in the district. Once it has completed the study, Syra Health will also provide a detailed report of its outcomes.

“Our mixed methods researchers, allow us to deploy analytical and statistical tools necessary for producing this study,” said Srikant Devaraj, PhD, Vice President of Health Analytics, Syra Health. “We believe epidemiological studies like this one will benefit other states beyond Washington D.C., as the nation continues to wrestle with behavioral health conditions.”

“We are continuing to win contracts at a steady pace,” said Dr. Deepika Vuppalanchi, CEO of Syra Health. “Our pipeline of contracts remains robust, and we expect to announce more wins as they are executed.”

ABOUT SYRA HEALTH

Syra Health is a healthcare technology company addressing some of healthcare’s most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health’s products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government. For more information, please visit www.syrahealth.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include but are not limited to, statements relating to the expected use of proceeds, the Company’s operations and business strategy, and the Company’s expected financial results. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors outlined in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

For Media Inquiries:
Syra Health Corp.
Communications and Marketing Director
Christine Drury
317-385-9227
[email protected]

For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
[email protected] 

SOURCE Syra Health

CINCINNATI, Feb. 6, 2024 — ActionStreamer, the market-leading media streaming platform for IoT devices announced today the close of its $2.4M Series A funding round, led by JumpStart Ventures through the Advanced Manufacturing Fund, managed with support from MAGNET. The Castellini Management Company, owners of the Cincinnati Reds, also co-invested in the round.

With the successful completion of Series A financing, ActionStreamer is poised to strategically deploy capital to accelerate the development of its patented comprehensive technology platform. The platform encompasses a robust API and SDK offering, reference hardware and applications, coupled with advanced cloud services. The platform enhancements will further advance ActionStreamer’s mission to unlock pioneering data streaming capabilities and media solutions that serve diverse enterprise markets, including the sports and entertainment, aerospace, and industrial sectors, as well as remote surveillance and monitoring.

“We are thrilled to welcome JumpStart Ventures as our lead investor, as their support represents a substantial investment and provides us with invaluable experience and guidance as ActionStreamer scales,” said CEO, Bob Lento. “This raise will drive the evolution of our software and cloud service products for the enterprise marketplace, empowering thousands of customers to stream data with the click of a button at any time, from anywhere in the world.”

Founded in 2016 by former NFL Linebacker Dhani Jones and Cincinnati technology entrepreneur Chris McLennan, ActionStreamer’s first market application was wearable point-of-view cameras and streaming solutions that have been showcased in NFL, MLB, USFL, SailGP, and RedBull events. In 2020, ActionStreamer was awarded a contract from the U.S. Air Force to develop an advanced communications system with real-time point-of-view video and two-way audio capabilities for use in confined spaces and hazardous areas. Most recently, ActionStreamer pioneered new 5G capabilities in collaboration with T-Mobile, and delivered the first Amazon Web Services-qualified 5G cameras on the Amazon Partner Network (APN).

“We are thrilled to partner with ActionStreamer to provide capital and support that will help realize the potential of this truly unique platform technology,” said Jerry Frantz, President of JumpStart Ventures. “The impact in sports, entertainment, defense and telecommunications as well as the ability to provide solutions in remote or challenging environments, illustrates the vast market potential of ActionStreamer’s cutting-edge data movement technology.”

About ActionStreamer
ActionStreamer is a proprietary technology and software platform for streaming media from wearable, IoT, and other connected devices. Founded in 2016, the end-to-end streaming platform has been widely recognized for delivering breakthrough data movement solutions and real-time omnichannel media offerings across the sports, entertainment, telecommunications, industrial, and defense markets, and a customer portfolio that includes the U.S. Air Force, FOX Sports, Amazon Web Services, and T-Mobile.

About JumpStart Ventures

JumpStart Ventures is a division of JumpStart Inc. investing in Seed and Series A-stage technology startups throughout Ohio and beyond. With four investment funds under management, the organization provides a capital continuum to startup founders as they move through critical growth phases. Financial returns generated by JumpStart Ventures help strengthen the competitiveness of Ohio’s VC ecosystem, increasing capital access and resource connections for early-stage companies. As one of Ohio’s most active seed-stage investors, the organization’s investment activities have generated 2.5X+ returns-to-date via nationally recognized exits. To learn more, visit JumpStart. VC.

SOURCE ActionStreamer